Once-daily Medication for Diabetic Patients

Janumet XR Launch Malaysia

Improving glycaemic control for people with diabetes can be a convenient, once-daily routine with the launch of JANUMET®. Developed by MSD, one of the leading healthcare companies in Malaysia, JANUMET® is an oral type 2 diabetes once-daily medication for diabetic patients that combines sitagliptin phosphate with extended-release metformin hydrocloride (HCl).

Approximately 1.9 million people in Malaysia and 382 million people worldwide have diabetes, a disease in which the body is able to produce insulin but either this is not sufficient or the body is unable to respond to its effects (also known as insulin resistance), leading to a build-up of glucose in the blood.

Given the high prevalence of the disease, it is becoming more and more important that making the management of the disease as convenient as possible is made a priority by drug companies.

In the words of Prof Chan Siew Pheng, Senior Consultant Endocrinologist, “As Type 2 Diabetes Mellitus (T2DM) is a chronic and progressive disease, many people with diabetes will eventually require multiple medications to help control their blood sugar. Fixed-dose combination therapy will help to reduce pill burden and improve compliance,” she said, at the official launch event of Janumet® XR held earlier today.

Janumet XR Launch Malaysia
Dr. Zanariah and Prof. Chan at the launch of Janumet XR, 3rd March 2015, Malaysia.



According to Dr Zanariah Hussein, Senior Consultant Endocrinologist, who was also present during the launch event, people with diabetes will suffer from various complications such as heart disease and stroke, vision loss and blindness, kidney failure and lower limb amputation if left untreated.

“Managing type 2 Diabetes such as making healthy food choices, regular exercise, taking diabetes medicines exactly as doctor prescribes and monitoring blood sugar are essential steps that will keep your blood sugar level closer to normal, which can delay or prevent complications, hyper-glycaemia, each scenario presenting diabetes patient with life-threatening complications.




JANUMET® targets three key defects of type 2 diabetes: insulin deficiency from pancreatic beta cells,insulin resistance, and overproduction of glucose by the liver. JANUMET® medicines, sitagliptin phosphate and metformin HCI extended-release, each which demonstrated ability to improve blood sugar control without increasing the risk of hypoglycaemia (low blood sugar).

Metformin works by decreasing glucose production in the liver, decreasing glucose uptake in the gut, and improves insulin sensitivity by increasing glucose uptake by muscle cells from the blood.

Sitagliptin, a once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing insulin synthesis and release from pancreatic beta cells as well as by decreasing overproduction of glucose by the liver in a glucose dependent manner frequency of medication i.e. once-daily compared to twice or three times daily, resulted in higher patient’s compliance.